Skip to main content
. Author manuscript; available in PMC: 2020 May 13.
Published in final edited form as: Mol Pharm. 2019 Dec 19;17(1):327–337. doi: 10.1021/acs.molpharmaceut.9b01091

Figure 1.

Figure 1.

Treatment with 4MU/HLX increases [89Zr]Zr-DFO-trastuzumab binding to HER2-expressing JIMT1 breast cancer cells.(A) Membrane-bound and internalized [89Zr]Zr-DFO-trastuzumab in JIMT1 breast cancer cells before and after treatment with 4MU, HLX, or 4MU/HLX (bars, n = 3, mean ± S.E.M, **P < 0.01 based on a Student’s t-test and compared with control). Cells were treated with 1 mM 4MU for 48 h, 1 Unit HLX for 2 h, or 4MU/HLX in the presence of 1 μM [89Zr]Zr-DFO-trastuzumab for 1.5 h. (B) Binding kinetics of [89Zr]Zr-DFO-trastuzumab in control, 4MU, HLX, or 4MU/HLX-treated JIMT1 cells. JIMT1 control and treated cells were incubated with [89Zr]Zr-DFO-trastuzumab (0−256 nM) for 3 h at 4 °C (upper panel). Data are presented as the mean ± S.E.M, n = 3. Binding parameters (lower panel) of 89Zr-labeled trastuzumab to JIMT1 control and treated cells (*P < 0.05 based on a Student’s t-test and compared with control).